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Summary.-Patients with advanced malignant disease show an apparent lesser
degree of lymphocyte sensitization to cancer antigen when tested under standard
conditions than do early cases. In the serum of cancer patients there is a lympho-
cyteresponse depressingfactorwhosetitre risesastheneoplasmbecomesmore exten-
sive. The low lymphocyte response shown by advanced cancers is not, however,
directly referable to this rise in depressive factor, but to removal by the tumour
mass of specifically sensitized lymphocytes so that amongst the standard number
of cells under routine test an adequate number does not remain to give a full
response. Increasing the number of cells under test restores the result to the level
found in moderately sized cancers. The " absorptive capacity" of large tumours for
circulating sensitized lymphocytes is greater than can be provided by natural im-
munization produced by the tumour. Active immunization with a tumour antigen
can be expected therefore to increase lymphocyte-associated defence against cancer.
IT has previously been reported (Field
and Caspary, 1970) that patients suffering
from malignant neoplasia show lympho-
cyte sensitization to encephalitogenic fac-
tor (EF)-a low molecular weight basic
protein isolated from human brain (Cas-
pary and Field, 1965) and capable of
producing allergic encephalomyelitis in
guinea-pigs when injected (with Freund's
complete adjuvant) in very small doses.
Later it was found that a similar small
protein antigen could be isolated from
a variety of malignant tumours and
that lymphocytes from patients with
such tumours showed even higher sensi-
tization to this than to EF (Caspary and
Field, 1971). As our series of cases
grew, it became apparent that patients
with advanced malignant tumours in
general gave lower results than did early
ones. Under the stimulus of a similar
observation by an independent group of
workers (Joslin, Pritchard, Sutherland
and Moore-private communication) a
more detailed study of the phenomenon
has been undertaken and is presented
here. It emerges that in cancer alympho-
cyte depressive factor (LDF) appears in
the serum and rises markedly in titre as
the tumour progresses. The occurrence
of this factor may be a particular instance
of a general phenomenon which accom-
panies lymphocyte sensitization though
its biological significance is uncertain.
However, the part played by LDF in
producing the low observed values in
advanced cancers is not clear, since there
is also evidence that a large tumour mass
filters target-sensitized cells out of the
circulation, leaving insufficient numbers in
the blood to give the considerably higher
result shown by smaller tumours under
the standard conditions of test.
MATERIALS AND METHODS
Studies have been carried out on 17
patients with advanced carcinoma and on
a further 37 patients with moderately
advanced or early tumour by the macrophage
electrophoresis method described in extensoLYMPHOCYTE SENSITIZATION IN ADVANCED MALIGNANT DISEASE
(Field and Caspary, 1970, 1971; Caspary and
Field, 1971), but orientated towards eliciting
the reason for the tendency to low values
in advanced malignancy. For comparison,
13 subjects with non-malignant or " pre-
malignant" disease have also been studied.
In principle, the method depends upon
interaction ofantigen with sensitized lympho-
cytes to liberate a protein (Caspary, 1971)
with the property of causing normal macro-
phages to travel more slowly in an electric
field (macrophage slowing factor-MSF).
This factor may be identical with macrophage
migration inhibitory factor (MIF). Normal
guinea-pig macrophages are thus used as
an indicator system to detect antigen-
lymphocyte interaction. In practice, normal
guinea-pig macrophage exudate is raised by
intraperitoneal inoculation of sterile liquid
paraffin and harvesting the cells 8-16 days
later. This exudate contains 10-20% of
lymphocytes and since these may enter
into a mixed" reaction when brought
into contact with human lymphocytes, the
exudate is exposed to 100 rad of y-irradiation
from a Cobalt bomb which incapacitates-at
least temporarily-the guinea-pig lympho-
cytes (Field and Caspary, 1971; Hughes and
Paty, 1972). It should be noted that
100 rad is effective only against unsensitized
lymphocytes. If, however, the guinea-pig
lymphocytes are sensitized then even 500 rad
w%Aill not abolish their reactivity. This has
been found by direct experiment.
Lymphocytes are prepared from about
18 ml of venous blood by removing poly-
morphs w-ith carbonyl iron and methyl
cellulose (Hughes and Caspary, 1970). In
carrying out a routine test, 0.5 x 106
lymphocytes from the patient are mixed
with 107 irradiated normal guinea-pig macro-
phages in medium 199 and incubated without
addition of antigen for 90 minutes at 20° C.
In other experiments, where the effect of
making available a larger number ofsensitized
cells was to be studied, 2-5 or 5 0 million
lymphocytes have been used. The migra-
tion speed of the macrophages is then
estimated and constitutes the control time.
To other mixtures of lymphocytes and
macrophages the antigens to be tested are
added-usually at 33 yig/ml final concentra-
tion. Antigens used in this study have
been PPD-purified protein derivative of
tubercle; encephalitogenic factor (EF)-a
small basic protein prepared from normal
human brain (Caspary and Field, 1965),
measles virus (grown in LLC-MK2 cells),
and a number of antigens prepared in the
same way from different human tumours,
especially one from a cancer of the cervix
(Caspary and Field, 1971). After incuba-
tion, the time of macrophage migration is
again estimated. all measurements being
made " blind ", i.e. the specimens numbered
and the results later decoded. For each
assessment, 10 cells are timed in both direc-
tions of the potential difference in a Zeiss
cytopherometer. A complete account-with
a detailed original protocol-has been pre-
sented by Caspary and Field (1971). In
order to estimate macrophage retardation,
the slowing induced by the antigen-lympho-
cyte interaction is expressed as a percentage
of the control time. Thus if t -= control
time, i.e. mean migration time when no
antigen present and te = experimental time,
i.e. when antigen is present, then in general
te > tc, and [(te- tc)ltc] x 100 is a measure
of antigen-lymphocyte interaction and so
of sensitization. These percentages are the
figures presented in the tables.
Tests are ordinarily carried out in
medium 199. Lymphocyte depressor activity
is estimated by incorporating varying dilu-
tions of serum in the system and recording
the reduction in percentage slowing in
each case. In this way the lymphocyte
depressing factor (LDF) may be titred and
the dilution which fails to influence the
result in medium 199 can be determined.
In some cases LDF has been titred out
with respect to autologous cells; in others
it has been titred on homologous cells (i.e.
from other patients with cancer).
RESULTS
A. Lymphocyte depressive factor. In
normal subjects and in those with benign
tumours (Table I) the titre of LDF in
the serum never exceeds 1: 60, with 3
exceptions. One is a laboratory worker
continually exposed to encephalitogenic
factor (EF)-which shares antigens with
PPD- and who shows 10.6%o sensitiza-
tion to EF. The other 2 are apparently
normal women who are Mantoux negative
and who have repeatedly failed to convert
after BCG vaccination. These 2 subjects
show the widespread sensitization asso-
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TABLE I.-Normal Subjects and Patients with Benign Neoplasia
(a) Lymphocyte depressive factor (LDF) in serum
Age
20
24
24
28
28
28
30
33
34
34
34
39
43
48
48
51
56
Titre of LDF
60 120 240
+- -
+ -
± -
+ -
± -
+ -
± -
+ -
+ -
+ -
+ -
+ -
± + -
+
±
+ -
± -
Antigen
Ca
EF
EF
Ca
Ca
Ca
EF
Ca
Ca
Ca
Ca
Ca, EF
PPD
EF
Ca
Ca
PPD
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
18t . F . 45 . + + + . PPD . Non-converter
19t . F 40 . + + - . PPD . Non-converter
(b) Pregnant women
Weeks
Patient pregnant
1 . 12
2 . 40
3 . 10
4 . 40
(c) Benign neoplasia
Patient Sex A
1 .F .1
2 .F .2
3 .F 3
4 .F 3
5 .F 3
6 .F .4
7 .F .4
8 .F .4
9 .F .
Age 60
22 . +
23 . +
31 . +
31 . +
.ge
19
27
31
34
39
40
45
47
50
60
+
+
+
120 240 480 960 Antigen
+ . PPD
+ + + + . PPD
+ . PPD
+ + + + . PPD
120 240 Antigen
Ca
Ca
Ca
Ca
Ca
Ca
Ca
Ca
Fibroadenoma of breast
Fibroadenoma of breast
Fibroid uterus
Fibroid uterus
Fibroid uterus
Fibroid uterus
Fibroid uterus
Fibroid uterus
Fibroid uterus
* Laboratory worker exposed to EF and sensitized to it (10- 6%).
t Non-converter with BCG.
ciated with sarcoidosis (Caspary and
Field, 1971). During pregnancy there is
a rise in LDF and an abridged version
of the results obtained by Smith, Caspary
and Field (1972) is included in the table.
The patients presented here are typical.
In patients suffering from precan-
cerous conditions such as leukoplakia or
a locally malignant tumour (basal cell
carcinoma; haemangiopericytoma), LDF
is increased somewhat in the serum. The
increase is, however, much more dramatic
in patients with malignant neoplasias.
Altogether, the serum from 40 patients
with malignant neoplasia has been titred
for suppressive activity against the cells
of other cancer patients (i.e. in the
homologous situation). In the case of 33
of these sera, the degree of sensitization
of the cells associated with each serum
(i.e. the sensitization of the patient from
whom the serum was drawn) was known,
so that for these 33 sera the correlation
between degree of lymphocyte sensitiza-
tion and LDF appearing in the serum
(when tested in the homologous situation)
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Patient
1
2
3
4
5
6
7
8
9
10
11
12
13*
14
15
16
17
Sex
M
M
F
F
M
M
M
M
M
M
M
M
M
F
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TABLE HJa.-Homologou8 Situation
% sensitization
with cancer cervix
antigen
7-1
6-6
7-2
8-5
5.9
8-3
8-0
6-2
4-1
7-2
9.7
7*8
6*4
6-8
9*2
Age
45
45
47
54
56
59
60
64
66
68
69
70
75
76
77
78
LDF
1920++
. 3840+
. 3840
. 1920
. 3840
. 3840++
. 1920+
. 7680+
. 7680+
. 3840
. 7680+
. 3840+
. 3840+
. 3840
. 3840+
% sensitization
with cancer cervix
antigen
11*0
15*4
13*5
16-0
16*2
15*6
15.0
16*5
15.9
17*9
15-1
16-6
15*4
17*3
14*0
13-8
LDF
480+
240
480
240
240
240
240
240
240
240
240
240
240
240
240
240
Rapid cancer (Ca) breast
Fungating Ca breast
Ca ovary
Ca breast fungating
Ca cervix
Ca ovary
Ca rectum
Ca lung
Lymphosarcoma
Ca lung with sec.
Terminal Ca bladder
Ca breast
Ca bladder
Ca bronchus advd.
Fungating Ca breast
Ca lung
Ca colon
Ca lung
Ca breast
Ca breast
Ca lung
Ca mouth
Ca bladder
Ca thyroid
Ca breast
Ca lung
Ca colon
Ca colon
Ca bladder
Ca bladder
Ca lung
* Also tested in autologous situation (Table llb).
TABLE Ilb.-Autologous Situation
Advanced
cancer Sex Age
M.S. .F .60
O.W. .M .63
M.M. .F .70
T.D. . M . 70
P.R. . F . 83
Moderate
cancer Sex Age
L.R. .F .18
D.R. . F . 45
E.L. .F .45.
O.E. .F .46.
M.N. . F . 50
R.O. .F .56
J.A. .F .59.
W.S. . M . 77
% sensitization
with cancer cervix
antigen
8*3
8*0
7 8
9.7
9-2
% sensitization
vith cancer cervix
antigen
13*9
15-4
15*3
14-3
13*0
17*4
13-0
14*0
LDF*
1920+
1920
960+
7680+
1920+
LDF*
480+
480
480+
240
240
240
240
240
Ca ovary
Ca rectum
Ca breast
Terminal Ca bladder
Fungating Ca breast
Lymphosarcoma
Ca colon
Ca breast
Basal cell Ca
Ca colon
Melanoma with metastases
Ca breast
Ca bladder
* LDF = titre of lymphocytes depressing factor. The assessment of stage of cancer was made on
clinical grounds-size of mass, local and distant spread, etc.
Advanced
cancer
J.D.
H.M.
M.I.
L.S.
R.R.
M.S.*
O.W.*
G.D.
D.W.
C.H.
T.D.*
M.M.*
A.F.
E.A.
P.R.*
Sex Age
F . 32
F . 37
F 46
F 46
F . 53
F . 60
M 63
M . 67
M . 68
F . 69
M . 70
F . 70
F . 76
M . 83
F . 83
Moderately
advanced
cancer
W.K.
D.R.*
J.McK.
D.B.
E.E.
E.G.
W.G.
J.S.
M.E.
M.McC.
D.M.
D.H.
A.H.
A.R.
W.S.*
W.R.
Sex
M
F
M
F
F
M
M
M
F
F
F
F
M
M
M
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Patient
H.F.
P.S.
O.E.
J.B.
G.P.
G.P.
Sex
F
M
F
M
F
F
Age
13
44
46
52
66
68
TABLE IIC
% sensitization
with cancer cervix
antigen
9 4
9-7
14-3
11-8
11-4
could be studied. Results are shown in
Table Ila. It will be seen there is a
clear differentiation between the sensi-
tization shown by clinically well advanced
cases of neoplasia (as judged clinically by
size and fixity of growth as well as local
and distant metastases) and those which
are only moderately advanced, the LDF
titres in the former being much higher
LDF
240
240
240
240
120
120
Haemangiopericytoma
Basal cell carcinoma
Basal cell carcinoma
Basal cell carcinoma
Leukoplakia tongue
Leukoplakia tongue
than in the latter. The correlation coeffi-
cient between % lymphocyte sensitiza-
tion and LDF titre (when measured in
the homologous situation) is - 0-8156
(P < 0.001).
Serum from 15 patients has been
tested in the autologous situation (i.e.
against own lymphocytes) (Table Ilb).
As before, there is a similar clear division
TABLE IIIa.-Cancer Patients
Cancer cervix
millions
lymphocytes
0-5 2-5 5-0
7-6 11-8 14-1
8-6 - 12-9
9-1 14-2 -
7-1 13-9 -
5 M . 71 . 8-4 12-1 14-5 .
6 . M . 53 . 11-6 16-1
7
8
9
10
11
12
13
F
F
F
F
73
60
49
51
9-3 13-3 15-5
6-3 9-9 12-6
10-1 12-7 14-9
8-1 13-9 15-6
F . 72 . 13-0 15-3
. F . 76 . 14-1 15-1
F . 47 . 16-2 16-7
15-7 .
15-6
14 . M . 64 . 7-6 12-5
15 . F . 84 . 9-9 13-6 .
16 . M . 66 . 8-3 13-5 .
17 . M . 58 . 6-2 12-1
18 . M . 61 . 7-2 - 10.8* .
19 . F . 77 . 7-3 - 11-5 .
20 . F 38 6-7 12-6 6
Measles
millions
lymphocytes
0-5 2-5 5-0
PPD
millions
lymphocytes
0-5 2-5 5-0
- . --- . Recurrent Ca colon
13-8t 15-8t Ca breast
12-1 11-5 - . 15-9t 18-It . DiffuseCaperitoneum
10- 2 10-4 . 13-2$ 15-4 - . Ca breast: multiple
metatasis
- 13-6§ 16-6§ Simple mastectomy,
December 1971
12-6 11-9 - . - - - . Ca kidney; 1969 re-
current mass
- - . Ca ovary: sec.
- - - Ca colon: recurrent
10-3 11-3 - . Ca ovary: solid pelvis
- - Ca cervix: pelvic
spread
-.- - . Ca bronchus
. Ca bladder
-. - . Ca breast: moder-
ately advanced
11-3 14-9 Large inoperable Ca
stomach
13-2 - 17-1 Large inoperable Ca
stomach
8-5 - 8-7 7 12-6 - 16-6 6 Ca prostate: skeletal
metastases
- - . 11-4 1 6-6 - . Recurrent Ca rectum
with metastases
8-5 8-4* - Advanced Ca bronch-
us with metastases
- 11-9 - 14-8 . Fungating Ca breast
8-6 8-7 - - . Advanced Ca ovary
* Only 4-5 million cells available for test.
t P = 0- 1-0-05 (not significant).
t P = 0-05-0-025.
§ P = 0-01-0-005.
With the S.D. of measurements obtained, a % change > 2-5% means P < 0- 01.
Patient Sex Age
1 . M . 68 .
2 . F . 57 .
3 . M . 52 .
4 . F . 57 .
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TABLE IlIb. Normal and Non-malignant Subjects
Ca cervix
millions
lymphocytes
Patient Sex Age 0 5
A . M . 29 .
B . M . 43 .
C . AM . 56 . 3-6
D . M . 70 . 1-7
E . M . 58 . 4-1
F . AI . 64 4-4
G
H
I
,J
K
L
M
N
0
p
Q
R
S
T
U
F
F
F
M
F
F
F
F
F
F
F
F
F
M
M
65 . 3-7
80 . 4 0
78 . 3-3
69 . 3-2
19
23
28 . -
18 . --
22 . 1-3
19
25
34
40
32 . 4-9
26 . 1-3
2-5 5 0
2-8
2-8
4-8
2-9
3-7 3.3
3.9
3-8 .
1-8
4-6 .
1-6
Measles
millions
lymphocytes
0 5 2-5 5 0
10-8 - 11-2
9-7 10-2
3.-7 4.4
120 119
12-0 -12-5
PPD
millions
lymphocytes
0 5 2-5 5 0
16-4 16- 7 -
18-5 19-4 -
17- 1
4-3
5.5
3.9
3.4
5-2
5-3
14-2
14-9
18-7
17-5
17-3
3.5
5-6 4.4
4-4 5-8 .
3 0
7 - 2 .
5 -1
5 0
15-3
16 -1
- 18-7 .
- 17-8 .
Normal
Normal
Normal
Benign hypertrophy prostate
Benign hypertrophy prostate
? Normal: intermittent claudi-
cation
Normal
Normal
Normal
Normal
Pregnant, 38 weeks
Pregnant, 40 weeks
Pregnant, 38 weeks
Pregnant, 36 weeks
Pregnant, 37 weeks
Pregnant, 40 weeks
Pregnant, 40 weeks
Post partum, 7 days
Post partum, 9 days
Normal
Normal
Patients A-I have also been tested with EF (encephalitogenic factor): as with cancer antigen no signi-
ficant increase results from raising the number of cells from 0 5 to 2 5 millions.
between the clinically markedly advanced
cases and the moderately advanced; the
correlation coefficient between cell sensi-
tization and LDF titre is - 05655
(P = 0.02-0-01). For comparison, the
serum of a few cases of leukoplakia and
basal cell carcinoma are shown in Table
lIc. The LDF titres tend to be low.
In one case serum was active in titre in
excess of 1: 7840 both against own and
other cancer lymphocytes, and another
showed a titre > 1: 7840 against other
cells. Titres greater than 1: 3840 are
not uncommon and are higher than
those we have encountered in multiple
sclerosis or sarcoidosis (Field and Caspary,
1971).
Thus, in general, lymphocytes from
patients with advanced malignant disease
show an apparently low degree of sensi-
tization when tested under standard
conditions and this correlates strongly
with the high level of LDF in serum.
B. Effect of increasing number of
lymphocytes undertest. Earlyexperiments
during development of the method had
shown that 0-5 X 106 cells are "on the
plateau" response when the test is
carried out with increasing cell numbers.
However, when unexpectedly low results
were found with advanced cancers, further
experiments were set up in which 2.5
millions or 5 0 millions of lymphocytes
were used instead of half a million.
With these higher numbers of cells the
result achieved rose into the lower end
of the expected range (Table III). On
the other hand, increasing the number of
cells when measles was used as antigen
did not materially affect the result
amongst the cancer patients.
With PPD as antigen, a larger number
of cells gave no higher result in normal
subjects but did give an increase in
advanced cancer patients.
Thus it appears that in advanced
cancer patients, amongst 0*5 million cells
there are not enough sensitized cells to
give a maximal result whereas there are
enough to give a full measles response.
With PPD there were again not enough
cells in 0-5 millions to give a full result
in advanced cancer but there were enough
in normal people. It can be concluded
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that the absolute number of circulating
lymphocytes sensitized to cancer antigen
or to PPD is diminished in advanced
cancer.
DISCUSSION
The occurrence of a lymphocyte reac-
tivity depressive factor (LDF) in serum
was noted by Kamrin (1959) whilst
Mowbray (1963a, b) and Mowbray and
Hargrave (1966) found that a serum
factor could diminish antibody response
in experimental animals. Cooperband et
al. (1968) claimed that the suppressive
factor was located in the a globulin
fraction of serum. More recently Riggio
et al. (1969) have associated this depres-
sive activity with the °C2 globulin com-
ponent of serum. In this Unit, Ford
and Caspary (unpublished data) have
found LDF to be associated exclusively
with the °C2 macroglobulin component of
normal and multiple sclerosis serum. An
indication ofsuppressive factor in multiple
sclerosis serum had previously been re-
ported by Knowles et al. (1968) and
Hughes et al. (1968) using the lymphocyte
transformation method. Suppressive fac-
tor in serum has indeed been recorded in
a wide variety of pathological conditions
including tuberculosis (Heilman and Mac-
Farland, 1966); hepatitis (Paronetto and
Popper, 1970); ataxia telangiectasia (Mac-
Farlin and Oppenheim, 1969); secondary
syphilis (Levene et al., 1969); chronic
candidiasis (Canales et al., 1969); Hodg-
kin's disease (Trubowitz, Masek and del
Rosario, 1966); as well as cancer (Trubo-
witz et al., 1966; Salk, 1967; and others).
With the present highly sensitive and
quantitative method of assessing lympho-
cyte sensitization, the titre of LDF in
health and disease can readily be deter-
mined. It appears that elevation of the
level of LDF is an invariable concomitant
of special lymphocyte sensitization and
might constitute a " braking mechanism "
built into the cellular immunological
response to antigen. Whilst in some
conditions studied (neurological disease,
sarcoidosis) the serum is active at high
dilution against own cells rather than
against those of another patient with the
same condition (Field and Caspary, 1971),
so that in a sense it is " tailor made "
to its own lymphocytes, this is not
apparent in the case of advanced cancer
where, if anything, a serum seems rather
more active in the homologous situation
than the autologous (Tables Ila, b).
Whilst no satisfactory explanation can
be offered for this difference, it may be
associated with the continuous and active
new antigenic stimulation in cancer.
Apart from malignant neoplasia LDF
may allow a fine regulation to be achieved
by means of an " accelerator-brake "
mechanism, bringing, however, in its
train the possibility of imbalance leading
to disease states. Thus failure of ade-
quate LDF production or function might
result in runaway aggression by lympho-
cytes which have become sensitized, for
one reason or another, to a constituent
of a target organ. If further study
supports this view in a disease, for
example, like multiple sclerosis, then
elevation of LDF would be a rational
therapy. On the other hand, a mechan-
ism which has been evolved to damp
down reaction to transient and bio-
logically unimportant antigens-e.g. as
may occur in banal infections-may
swing into action in a situation where
maximum lymphocyte reactivity would
be beneficial. One such situation is
defence against cancer. Under these con-
ditions it would be reasonable to direct
therapy towards lowering the level of
LDF so that lymphocyte activity towards
the cancer is unhindered. The negative
correlation between the degree oflympho-
cyte sensitization (as measured in 0.5
million cells) and LDF is very high,
both in the autologous and homologous
situations. Despite this, the biological
significance of this correlation in cancer
is dubious for the following reasons:
Normally 0-5 x 106 lymphocytes are used
in the test as usually carried out. If,
however, the number is raised five-fold
to 2-5 X 106 then the previously low
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value in advanced cancer rises to the
expected 15% or so. The simplest inter-
pretation is that the large tumour mass
" sponges up " so many sensitized lympho-
cytes from the circulation that an inade-
quate number remains amongst 0 5 x 106
cells to give a full result. Whilst the
tumour continues to sensitize more lymph-
ocytes, its absorptive capacity outstrips
its immunizing ability. If this is the
true interpretation, then it supports the
view that further active immunization
would raise the number of sensitized
(defensive) lymphocytes and offers encou-
ragement for immunization therapy as
an effective treatment of cancer.
Increasing the number of lymphocytes
when testing with measles antigen does
not increase the result in cancer patients
(Table III). As would be expected in
the absence of a " sponging up " process
from the circulation, the half million is
adequate to give a maximal result. In
the few cases so far tested, the result is
raised if the number of cells used is
increased when PPD is the antigen. A
systematic study of cellular sensitization
to PPD in advanced cancer is now in
progress using 0.5, 2-5 and 5-0 X 106
cells. It is known that PPD shares
antigenic determinants with encephalito-
genic factor (EF) derived from human
brain (Field et al., 1963) and that cancer
basic protein, EF and PPD are anti-
genically related, PPD being further
removed from cancer antigen than is
EF (Field, Caspary and Carnegie,
1971). This antigenic relationship between
PPD and cancer antigen would mean
that PPD sensitized cells might also be
" sponged up " by a large tumour mass
and that the result obtained, when
lymphocyte sensitization to PPD is tested
for, will be greater if a large number of
cells is used. This might explain, too,
the apparent success of BCG immuno-
therapy in acute lymphoblastic leukaemia
claimed by Mathe et al. (1969) and usually
attributed to " nonspecific " stimulation
of the lymphocytic defensive system.
In the present interpretation such immu-
nization would increase the number of
cells sensitized to the neoplastic tissue,
for BCG would not be a " nonspecific "
antigen but a specific one-albeit probably
not the best which can be made.
In advanced pregnancy where the result
with 0 5 x 106 cells is low, stepping up
the number to 2-5 X 106 has no effect.
It would appear then that amongst such
cases the response is maximal with
0-5 x 106 cells and that the depression
in pregnancy may reside in the cells
themselves or be due to LDF (Smith et
al., 1972) and is not due to deficient
number of cells.
An alternative explanation for the
failure of 0 5 million cells to give a full
response whereas 2.5 millions do so,
might be depressed reactivity of those
lymphocytes which are sensitized to
tumour antigen. Whilst the evidence is
to some extent contradictory (Gatti,
Garrioch and Good, 1970), perhaps on
account oftechnical differences, the major-
ity of workers have reported no difference
in the ability of lymphocytes in (non-
lymphoproliferative) neoplasia to respond
to PHA stimulation (e.g. Robinson and
Hurvitz, 1966; Benezra and Hochman,
1971; and others). Some of the dis-
crepancies may well be due to inadequate
washing of lymphocytes since LDF titre
may on occasion be very high in advanced
cancer (> 1: 7960). Moreover, there is
some evidence that cells which are
sensitized to tumour antigen are stimu-
lated even more by PHA (Chu et al.,
1967; Frenster and Rogoway, 1970).
Hence, if the proportion of tumour
sensitized cells is reduced in the blood in
advanced cancer a lowered PHA response
(even making allowance for the com-
plicated nature of recruitment) might be
expected. In other words, some of the
reported reduced responses to PHA may
be attributable not to intrinsic depressed
capacity of the lymphocytes, but to
diminished absolute numbers in advanced
neoplasia.
Further experiment will show whether
all forms of advanced malignant tumour
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show the same low value in our test or
whether the absorptive capacity for
lymphocytes per unit mass of tumour
depends upon the nature of the tumour.
This would seem probable since growths
of differing constitution are likely to
differ in the facility with which they
allow the circulation of lymphocytes
within their substance with ready access
to antigenic immunizing sites. The
" sponging up " capacity of tumour with
respect to sensitized lymphocytes has
recently been suggested in the case of
leukoplakia of the tongue by Lehner
(1970). He found that when a lympho-
cyte transformation test was carried out
with autologous saline homogenates of
leukoplakic tissue a negative correlation
was established between '4C-thymidine
uptake of the lymphocytes in vitro and
the non-pyroninophilic mononuclear cell
infiltrations of the biopsies. The author
considered a possible explanation to be
the filtering out of sensitized (i.e. trans-
formable) cells in the tumour mass.
It is clear that elevated LDF levels
can coexist with increased lymphocyte
sensitization. This is seen in early and
moderately advanced malignant neoplasia
and in conditions such as sarcoidosis
(Caspary and Field, 1971). Whilst LDF
may not be important in producing the
low sensitization values found in advanced
cancer, it may be significant under more
physiological conditions. Here low re-
sults are not due to inadequate numbers
of PPD sensitized cells in the standard
0 5 million used. Lymphocyte reactivity
to PPD during pregnancy-especially as
it advances-is reduced, to be restored
within about 8 days of delivery. At
the same time, LDF presents a rise
during pregnancy and a return to normal
in the puerperium (Smith et al., 1972).
It should be noted that the low results in
advanced pregnancy are obtained in
medium 199, i.e. the high LDF serum
is excluded from the system, yet the low
reactivity of the cells persists. Whether
prolonged in vivo exposure to LDF
" switches off" the cells (to be made
reactive again in the puerperium, perhaps
under some hormonal influence) or there
is simply low intrinsic reactivity in
advanced pregnancy remains to be deter-
mined.
Finally, the possibility must also be
entertained that LDF may play a part
in the complex homoeostatic situation
which occurs in long-term cancer. It
seems possible that dissemination of
cancer cells occurs in many instances,
perhaps in the large majority of patients,
and is responsible for the very prolonged
maintenance of a clone ofcancer sensitized
lymphocytes even after apparent surgical
eradication (Caspary and Field, 1971;
Field, 1972). Immunosurveillance of
small foci of cancer cells (Burnett, 1969)
depends upon the activity of lympho-
cytes, which in turn is balanced against
LDF of serum. Elevation of LDF from
some extraneous cause might upset a
long maintained equilibrium, with escape
of the malignant cell nest from controls,
and so allow the development of a late
"secondary " growth.
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